Cargando…

A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma

Surgical excision is the standard treatment for basal cell carcinoma (BCC), but it can be challenging in elderly patients and patients with comorbidities. The non-surgical guidelines procedures are usually regarded as monotherapy options. This quasi-experimental, non-randomized, comparative effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Scurtu, Lucian G., Petrica, Marian, Grigore, Mariana, Avram, Alina, Popescu, Ionel, Simionescu, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224731/
https://www.ncbi.nlm.nih.gov/pubmed/35743507
http://dx.doi.org/10.3390/jcm11123439
_version_ 1784733440499777536
author Scurtu, Lucian G.
Petrica, Marian
Grigore, Mariana
Avram, Alina
Popescu, Ionel
Simionescu, Olga
author_facet Scurtu, Lucian G.
Petrica, Marian
Grigore, Mariana
Avram, Alina
Popescu, Ionel
Simionescu, Olga
author_sort Scurtu, Lucian G.
collection PubMed
description Surgical excision is the standard treatment for basal cell carcinoma (BCC), but it can be challenging in elderly patients and patients with comorbidities. The non-surgical guidelines procedures are usually regarded as monotherapy options. This quasi-experimental, non-randomized, comparative effectiveness study aims to evaluate the efficacy of a combined, conservative, non-surgical BCC treatment, and compare it to standard surgical excision. Patients with primary, non-ulcerated, histopathologically confirmed BCCs were divided into a conservative treatment (129 patients) and a standard surgery subgroup (50 patients). The conservative treatment consisted of ablative CO(2) laser, cryosurgery, topical occlusive 5-fluorouracil, and imiquimod. The follow-up examinations were performed 3 months after remission, then every 3 to 6 months, and were extended with telephone follow-ups. Cosmetic-self assessment was recorded during a telephone follow-up. Subjects from the conservative subgroup presented a clearance rate of 99.11%, and a recurrence rate of 0.98%. No recurrences were recorded in the surgical group, nor during the telephone follow-up. There were no differences regarding adverse events (p > 0.05). A superior self-assessment cosmetic outcome was obtained using the conservative method (p < 0.001). This conservative treatment is suitable for elders and patients with comorbidities, is not inferior to surgery in terms of clearance, relapses, or local adverse events, and displays superior cosmetic outcomes.
format Online
Article
Text
id pubmed-9224731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92247312022-06-24 A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma Scurtu, Lucian G. Petrica, Marian Grigore, Mariana Avram, Alina Popescu, Ionel Simionescu, Olga J Clin Med Article Surgical excision is the standard treatment for basal cell carcinoma (BCC), but it can be challenging in elderly patients and patients with comorbidities. The non-surgical guidelines procedures are usually regarded as monotherapy options. This quasi-experimental, non-randomized, comparative effectiveness study aims to evaluate the efficacy of a combined, conservative, non-surgical BCC treatment, and compare it to standard surgical excision. Patients with primary, non-ulcerated, histopathologically confirmed BCCs were divided into a conservative treatment (129 patients) and a standard surgery subgroup (50 patients). The conservative treatment consisted of ablative CO(2) laser, cryosurgery, topical occlusive 5-fluorouracil, and imiquimod. The follow-up examinations were performed 3 months after remission, then every 3 to 6 months, and were extended with telephone follow-ups. Cosmetic-self assessment was recorded during a telephone follow-up. Subjects from the conservative subgroup presented a clearance rate of 99.11%, and a recurrence rate of 0.98%. No recurrences were recorded in the surgical group, nor during the telephone follow-up. There were no differences regarding adverse events (p > 0.05). A superior self-assessment cosmetic outcome was obtained using the conservative method (p < 0.001). This conservative treatment is suitable for elders and patients with comorbidities, is not inferior to surgery in terms of clearance, relapses, or local adverse events, and displays superior cosmetic outcomes. MDPI 2022-06-15 /pmc/articles/PMC9224731/ /pubmed/35743507 http://dx.doi.org/10.3390/jcm11123439 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Scurtu, Lucian G.
Petrica, Marian
Grigore, Mariana
Avram, Alina
Popescu, Ionel
Simionescu, Olga
A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma
title A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma
title_full A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma
title_fullStr A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma
title_full_unstemmed A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma
title_short A Conservative Combined Laser Cryoimmunotherapy Treatment vs. Surgical Excision for Basal Cell Carcinoma
title_sort conservative combined laser cryoimmunotherapy treatment vs. surgical excision for basal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224731/
https://www.ncbi.nlm.nih.gov/pubmed/35743507
http://dx.doi.org/10.3390/jcm11123439
work_keys_str_mv AT scurtuluciang aconservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT petricamarian aconservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT grigoremariana aconservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT avramalina aconservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT popescuionel aconservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT simionescuolga aconservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT scurtuluciang conservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT petricamarian conservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT grigoremariana conservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT avramalina conservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT popescuionel conservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma
AT simionescuolga conservativecombinedlasercryoimmunotherapytreatmentvssurgicalexcisionforbasalcellcarcinoma